: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Liver Cirrhosis

Free Subscription

Articles published in Hepatology
Retrieve available abstracts of 425 articles:
HTML format

Single Articles

May 2024

LIU H, Li H, Wang DX, Li T, et al
Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
Hepatology. 2024;79:E144-E145.
PubMed

DALBENI A, Mantovani A, Lombardi R, Ravaioli F, et al
Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Hepatology. 2024;79:E146-E147.
PubMed

DALBENI A, Lombardi R, Henrique M, Zoncape M, et al
Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
Hepatology. 2024;79:1107-1116.
PubMed Abstract available

AJMERA V, Tesfai K, Sandoval E, Lopez S, et al
Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
Hepatology. 2024;79:1098-1106.
PubMed Abstract available

April 2024

GUO C, Liu Z, Fan H, Wang H, et al
Machine learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis.
Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000879.
PubMed Abstract available

PRZYBYSZEWSKI EM, Bhan I, Yarze JC
Letter to the Editor: On the use of non-selective beta blockers in cirrhosis.
Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000888.
PubMed

GARCIA-TSAO G, Kaplan DE
Reply: On the use of non-selective beta blockers in cirrhosis.
Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000889.
PubMed

VOLK ML
Innovations in Healthcare Delivery for Patients with Cirrhosis.
Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000892.
PubMed

TAPPER EB, Warner MA, Shah RP, Emamaullee J, et al
Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi.
Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000856.
PubMed Abstract available

March 2024

Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis.
Hepatology. 2024 Mar 29. doi: 10.1097/HEP.0000000000000857.
PubMed

CRUZ C, Prado CM, Gillis C, Martindale R, et al
Nutritional aspects of prehabilitation in adults with cirrhosis awaiting liver transplant.
Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000818.
PubMed Abstract available

CULLARO G, Allegretti AS, Fenton C, Ge J, et al
The association between mean arterial pressure and acute kidney injury reversal among decompensated cirrhosis patients.
Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000858.
PubMed Abstract available

DIETZ-FRICKE C, Degasperi E, Jachs M, Maasoumy B, et al
Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis - a real world case series.
Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847.
PubMed Abstract available

MUNOZ AE, Rodger EG
Letter to the Editor: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000846.
PubMed

SHARPTON S, Loomba R
Response to Letter to the Editor: emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000848.
PubMed

BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
PubMed Abstract available

AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
PubMed Abstract available

KUMAR M, Venishetty S, Jindal A, Bihari C, et al
Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000817.
PubMed Abstract available

Erratum: An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
Hepatology. 2024;79:E105.
PubMed

NICOARA-FARCAU O, Han G, Rudler M, Angrisani D, et al
Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis.
Hepatology. 2024;79:624-635.
PubMed Abstract available

WANG F, Chen L, Kong D, Zhang X, et al
Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1alpha transcriptional complex.
Hepatology. 2024;79:606-623.
PubMed Abstract available

LEE BP, Dodge JL, Terrault NA
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
Hepatology. 2024;79:666-673.
PubMed Abstract available

February 2024

WONG YJ, Teng M, Sim A, Thet HM, et al
Full adherence to cirrhosis quality indicators is associated with lower mortality in acute variceal bleeding: Nationwide audit.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000793.
PubMed Abstract available

ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
PubMed Abstract available

PENG Z, Wei G, Huang P, Matta H, et al
ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000801.
PubMed Abstract available

CALTHORPE L, Chiou SH, Rubin J, Huang CY, et al
A modified hospital frailty risk score for patients with cirrhosis undergoing abdominal operations.
Hepatology. 2024 Feb 19. doi: 10.1097/HEP.0000000000000794.
PubMed Abstract available

PREMKUMAR M, Kajal K, Izzy M, Sihag BK, et al
Reply to 'liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus".
Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000792.
PubMed

AGRAWAL D, Ariga KK
Liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus.
Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000789.
PubMed

MENG Z, Zhou L, Hong S, Qiu X, et al
Myeloid-specific ablation of Basp1 ameliorates diet-induced NASH in mice by attenuating pro-inflammatory signaling.
Hepatology. 2024;79:409-424.
PubMed Abstract available

SINHA S, Hassan N, Schwartz RE
Organelle stress and alterations in interorganelle crosstalk during liver fibrosis.
Hepatology. 2024;79:482-501.
PubMed Abstract available

January 2024

TRIPODI A, Primignani M, D'Ambrosio R, Tosetti G, et al
Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis.
Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000756.
PubMed Abstract available

ROWE IA
Prediction of outcomes in patients with acute variceal bleeding.
Hepatology. 2024;79:15-17.
PubMed

BROWN AJ, Won JJ, Wolfisberg R, Fahnoe U, et al
Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice.
Hepatology. 2024;79:183-197.
PubMed Abstract available

CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Hepatology. 2024;79:39-48.
PubMed Abstract available

December 2023

HOFER BS, Brusilovskaya K, Simbrunner B, Balcar L, et al
Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis.
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000740.
PubMed Abstract available

JENG WJ, Chien RN, Liaw YF
Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000737.
PubMed

CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
PubMed

WIEGAND J, Franke A, Stein K, Trautwein C, et al
Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
PubMed

CHEN J, Tu T, Cohen C, Wang S, et al
Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000732.
PubMed

Erratum: Diabetes and cirrhosis: Current concepts on diagnosis and management.
Hepatology. 2023;78:E108.
PubMed

DESAI AP, Madathanapalli A, Tang Q, Orman ES, et al
PROMIS Profile-29 is a valid instrument with distinct advantages over legacy instruments for measuring the quality of life in chronic liver disease.
Hepatology. 2023;78:1788-1799.
PubMed Abstract available

ABERG F
Letter to the Editor: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
Hepatology. 2023;78:E101-E102.
PubMed

RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
Hepatology. 2023;78:E103-E104.
PubMed

MAIWALL R, Piano S, Singh V, Caraceni P, et al
Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections- Results from the ICA 'Global study' [EABCIR-Global Study].
Hepatology. 2023 Dec 1. doi: 10.1097/HEP.0000000000000653.
PubMed Abstract available

November 2023

GISH RG, Jacobson IM, Lim JK, Waters-Banker C, et al
Prevalence and characteristics of Hepatitis delta virus infection in patients with hepatitis b in the united states: An analysis of the All-Payer Claims Database.
Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000687.
PubMed Abstract available

PREMKUMAR M, Kajal K, Reddy KR, Izzy M, et al
Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000691.
PubMed Abstract available

HE S, Peng Y, Wei Q
Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry.
Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000685.
PubMed

SLOOTER CD, van den Brand FF, Lleo A, Liberal R, et al
Reply - Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000689.
PubMed

KARVELLAS CJ, Bajaj JS, Kamath PS, Napolitano L, et al
AASLD Practice guidance on Acute-on-chronic liver failure and the management of critically Ill patients with cirrhosis.
Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000671.
PubMed

D'AMICO G, Zipprich A, Villanueva C, Sorda JA, et al
Further decompensation in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements.
Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000652.
PubMed Abstract available

SEBASTIANI G, Milic J, Tsochatzis EA, Marzolini C, et al
Letter to the Editor: People living with HIV and NAFLD-A population left behind in the global effort for liver fibrosis screening?
Hepatology. 2023;78:E87-E88.
PubMed

TILG H, Adolph TE, Tacke F
Therapeutic modulation of the liver immune microenvironment.
Hepatology. 2023;78:1581-1601.
PubMed Abstract available

SONG Y, Wei J, Li R, Fu R, et al
Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-beta/SMAD signaling.
Hepatology. 2023;78:1433-1447.
PubMed Abstract available

BRAILLON A, Naudet F
Letter to the Editor: Medications promoting abstinence in alcohol-associated cirrhosis.
Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000656.
PubMed

October 2023

JENG WJ, Chien RN, Liaw YF
Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662.
PubMed

DENG R, Wang Z, Liu Y, Sun J, et al
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.
PubMed

GRATACOS-GINES J, Lopez-Pelayo H, Pose E
Reply: Medications promoting abstinence in alcohol-associated cirrhosis.
Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000660.
PubMed

SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
PubMed Abstract available

KAPLAN DE, Bosch J, Ripoll C, Thiele M, et al
AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000647.
PubMed

GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
PubMed Abstract available

DONGELMANS EJ, Sonneveld MJ, Janssen HLA
Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000639.
PubMed

LIAW YF, Jeng WJ, Chien RN
Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000641.
PubMed

MA S, Chew V
Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000626.
PubMed

PENNISI G, Enea M, Romero-Gomez M, Bugianesi E, et al
Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.
Hepatology. 2023 Oct 2. doi: 10.1097/HEP.0000000000000616.
PubMed Abstract available

CHEN W, Sun Y, Chen S, Ge X, et al
Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities.
Hepatology. 2023;78:1118-1132.
PubMed Abstract available

LI J, Lu X, Zhu Z, Kalutkiewicz KJ, et al
Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH.
Hepatology. 2023;78:1200-1208.
PubMed Abstract available

MINCIUNA I, Gallage S, Heikenwalder M, Zelber-Sagi S, et al
Intermittent fasting-the future treatment in NASH patients?
Hepatology. 2023;78:1290-1305.
PubMed Abstract available

CALZADILLA-BERTOT L, Jeffrey GP, Wang Z, Huang Y, et al
Predicting liver-related events in NAFLD: A predictive model.
Hepatology. 2023;78:1240-1251.
PubMed Abstract available

DE ANGELIS RIGOTTI F, Wiedmann L, Hubert MO, Vacca M, et al
Semaphorin 3C exacerbates liver fibrosis.
Hepatology. 2023;78:1092-1105.
PubMed Abstract available

September 2023

NAHON P, Layese R, Ganne-Carrie N, Moins C, et al
The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis.
Hepatology. 2023 Sep 29. doi: 10.1097/HEP.0000000000000615.
PubMed Abstract available

RINELLA ME, Lieu HD, Kowdley KV, Goodman ZD, et al
A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis.
Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000607.
PubMed Abstract available

GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
PubMed Abstract available

ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
PubMed Abstract available

SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al
Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589.
PubMed Abstract available

August 2023

GRATACOS-GINES J, Bruguera P, Perez-Guasch M, Lopez-Lazcano A, et al
Medications for alcohol use disorder promote abstinence in alcohol-related cirrhosis: results from a systematic review and meta-analysis.
Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000570.
PubMed Abstract available

JENG WJ, Chien RN, Chen YC, Lin CL, et al
Hepatocellular carcinoma reduced, HBsAg loss increased and survival improved after finite therapy in hepatitis B patients with cirrhosis.
Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000575.
PubMed Abstract available

CHIN A, Bastaich DR, Dahman B, Kaplan DE, et al
Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites.
Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000577.
PubMed Abstract available

GE J, Fontil V, Ackerman S, Pletcher MJ, et al
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis.
Hepatology. 2023 Aug 23. doi: 10.1097/HEP.0000000000000583.
PubMed Abstract available

CHANG X, Lv C, Wang B, Wang J, et al
The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.
Hepatology. 2023 Aug 23. doi: 10.1097/HEP.0000000000000563.
PubMed Abstract available

JIANPING D, Xi C, Guangwen C, Fankun M, et al
Dual elastography to discriminate adjacent stages of fibrosis and inflammation in chronic hepatitis B: A prospective multicenter study.
Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000566.
PubMed Abstract available

LV Y, Bai W, Zhu X, Xue H, et al
Development and validation of a prognostic score to identify the optimal candidate for preemptive TIPS in patients with cirrhosis and acute variceal bleeding.
Hepatology. 2023 Aug 18. doi: 10.1097/HEP.0000000000000548.
PubMed Abstract available

TREBICKA J, Garcia-Tsao G
Controversies regarding albumin therapy in cirrhosis.
Hepatology. 2023 Aug 7. doi: 10.1097/HEP.0000000000000521.
PubMed Abstract available

BOWLUS CL, Levy C
Optimizing treatment of primary biliary cholangitis: Is good, good enough?
Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
PubMed

DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
PubMed Abstract available

July 2023

SENZOLO M, Shalaby S, Grasso M, Vitale A, et al
Role of non-neoplastic portal vein thrombosis in the natural history of patients with cirrhosis and first diagnosis of hepatocellular carcinoma.
Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000538.
PubMed Abstract available

NOUREDDIN M, Truong E, Mayo R, Martinez-Arranz I, et al
Serum identification of At-Risk MASH: The Metabolomics-Advanced steatohepatitis fibrosis score (MASEF).
Hepatology. 2023 Jul 24. doi: 10.1097/HEP.0000000000000542.
PubMed Abstract available

GE J, Digitale JC, Pletcher MJ, Lai JC, et al
Reply: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection?
Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000536.
PubMed

HU Y, Li Z, He W, Wang X, et al
Letter to the Editor: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection?
Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000533.
PubMed

NARASIMMAN M, Hernaez R, Cerda V, Lee M, et al
Hepatocellular carcinoma surveillance may be associated with potential psychological harms of in patients with cirrhosis.
Hepatology. 2023 Jul 4. doi: 10.1097/HEP.0000000000000528.
PubMed Abstract available

CHEEMA MRS
Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
Hepatology. 2023;78:E18.
PubMed

LEE J, Westphal M, Vali Y, Boursier J, et al
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.
Hepatology. 2023;78:258-271.
PubMed Abstract available

PENNISI G, Enea M, Falco V, Aithal GP, et al
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
Hepatology. 2023;78:195-211.
PubMed Abstract available

ABOZAID YJ, Ayada I, van Kleef LA, Vallerga CL, et al
Plasma proteomic signature of fatty liver disease: The Rotterdam Study.
Hepatology. 2023;78:284-294.
PubMed Abstract available

KONG M, Dong W, Kang A, Kuai Y, et al
Regulatory role and translational potential of CCL11 in liver fibrosis.
Hepatology. 2023;78:120-135.
PubMed Abstract available

June 2023

TAPPER EB, Lai JC
Time to embrace PROMIS-29 as the standard health-related quality of life instrument for patients with cirrhosis.
Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000508.
PubMed

May 2023

JESUDIAN AB, Fortune BE
The PROs and cons of crystalline lactulose for suspected covert hepatic encephalopathy among patients with cirrhosis and activity impairment: Are we using the right assessments?
Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000497.
PubMed

CARR RM, Li Y, Chau L, Friedman ES, et al
An integrated analysis of fecal microbiome and metabolomic features distinguish Non-cirrhotic NASH from healthy control populations.
Hepatology. 2023 May 25. doi: 10.1097/HEP.0000000000000474.
PubMed Abstract available

LV Y, Han G
Reply: Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial.
Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000475.
PubMed

YIN HJ, Wan YM
Letter to the editor: Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial.
Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000476.
PubMed

KIM BK, Bergstrom J, Loomba R, Tamaki N, et al
Magnetic resonance Elastography-Based prediction model for hepatic decompensation in NAFLD; a Multi-Center cohort study.
Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000470.
PubMed Abstract available

TONON M, Balcar L, Semmler G, Calvino V, et al
Etiological cure prevents further decompensation and mortality in cirrhotic patients with ascites as the single first decompensating event.
Hepatology. 2023 May 17. doi: 10.1097/HEP.0000000000000460.
PubMed Abstract available

MALLET M, Silaghi CA, Sultanik P, Conti F, et al
Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis.
Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000456.
PubMed Abstract available

SANGHA K, Chang ST, Cheung R, Deshpande VS, et al
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
Hepatology. 2023;77:1702-1711.
PubMed Abstract available

RINELLA ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, et al
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
Hepatology. 2023;77:1797-1835.
PubMed

KNIGHT GM, Thornburg B, Salem R
Reply: Discussing the place of TIPS in non-cirrhotic patients with chronic extra hepatic portal vein occlusion refractory to standard of care therapy.
Hepatology. 2023;77:E93-E94.
PubMed

GU W, Queck A, Trebicka J, Praktiknjo M, et al
Reply: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis.
Hepatology. 2023;77:E101.
PubMed

NG CH, Chan KE, Muthiah M, Tan C, et al
Examining the interim proposal for name change to steatotic liver disease in the US population.
Hepatology. 2023;77:1712-1721.
PubMed Abstract available

ZHANG S, Wan D, Zhu M, Wang G, et al
CD11b + CD43 hi Ly6C lo splenocyte-derived macrophages exacerbate liver fibrosis via spleen-liver axis.
Hepatology. 2023;77:1612-1629.
PubMed Abstract available

AHMED A, Arshad MW, Ibrahim H
Letter to the editor: Variability in serum creatinine is associated with waitlist and post-liver transplant mortality in patients with cirrhosis.
Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000429.
PubMed

CULLARO G
Reply: Variability in serum creatinine is associated with waitlist and post-liver transplant mortality in patients with cirrhosis.
Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000434.
PubMed

April 2023

UFERE NN
Home is where the liver is?: moving beyond readmissions to time at home as a patient-centered and pragmatic quality measure in cirrhosis care.
Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000415.
PubMed

TAPPER EB, Ospina E, Salim N, Chen X, et al
Lactulose therapy for patients with cirrhosis, portal hypertension, and poor patient reported outcomes - the Mi-Kristal RCT.
Hepatology. 2023 Apr 18. doi: 10.1097/HEP.0000000000000408.
PubMed Abstract available

RAABE J, Kaiser KM, ToVinh M, Finnemann C, et al
Identification and characterisation of a hepatic IL-13 producing ILC3-like population potentially involved in liver fibrosis.
Hepatology. 2023 Apr 10. doi: 10.1097/HEP.0000000000000350.
PubMed Abstract available

HIRSCHFIELD GM, Shiffman ML, Gulamhusein A, Kowdley KV, et al
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hepatology. 2023 Apr 6. doi: 10.1097/HEP.0000000000000395.
PubMed Abstract available

VILAR-GOMEZ E, Vuppalanchi R, Gawrieh S, Samala N, et al
CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population.
Hepatology. 2023;77:1241-1252.
PubMed Abstract available

GUERRIERI F, Levrero M
HBV, mitochondrial stress, and liver fibrosis: chicken or the egg.
Hepatology. 2023;77:1088-1089.
PubMed

LIU Z, Tan M, Ding H
Letter to the Editor: Contrast-enhanced CT and liver surface nodularity for the diagnosis of portosinusoidal vascular disorder: a case-control study.
Hepatology. 2023;77:E71.
PubMed

YIP TC, Vilar-Gomez E, Petta S, Yilmaz Y, et al
Geographical similarity and differences in the burden and genetic predisposition of NAFLD.
Hepatology. 2023;77:1404-1427.
PubMed Abstract available

TORRES S, Ortiz C, Bachtler N, Gu W, et al
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis.
Hepatology. 2023;77:1228-1240.
PubMed Abstract available

March 2023

ELHENCE H, Dodge JL, Farias AJ, Lee BP, et al
Quantifying days at home in patients with cirrhosis: a national cohort study.
Hepatology. 2023 Mar 31. doi: 10.1097/HEP.0000000000000370.
PubMed Abstract available

TRIPATHI D, Reiberger T
Letter to the editor: portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management.
Hepatology. 2023 Mar 30. doi: 10.1097/HEP.0000000000000359.
PubMed

ELIAS G, Schonfeld M, Saleh S, Parrish M, et al
Sepsis induced endothelial dysfunction drives acute-on-chronic liver failure via Angiopoietin-2-HGF-C/EBPbeta pathway.
Hepatology. 2023 Mar 22. doi: 10.1097/HEP.0000000000000354.
PubMed Abstract available

HONG T, Xiong X, Chen Y, Wang Q, et al
Parathyroid hormone receptor-1 signaling aggravates hepatic fibrosis through upregulating cAMP response element binding protein-like 2.
Hepatology. 2023 Mar 21. doi: 10.1097/HEP.0000000000000333.
PubMed Abstract available

ALLAIRE M, Thabut D
Reply: portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management.
Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000358.
PubMed

SMITH ML, Wade JB, Wolstenholme J, Bajaj JS, et al
Gut microbiome-brain-cirrhosis axis.
Hepatology. 2023 Mar 6. doi: 10.1097/HEP.0000000000000344.
PubMed Abstract available

GE J, Digitale JC, Pletcher MJ, Lai JC, et al
Breakthrough SARS-CoV-2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study.
Hepatology. 2023;77:834-850.
PubMed Abstract available

UDOMPAP P, Therneau TM, Canning RE, Benson JT, et al
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population.
Hepatology. 2023;77:931-941.
PubMed Abstract available

CANIVET CM, Costentin C, Irvine KM, Delamarre A, et al
Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
Hepatology. 2023;77:920-930.
PubMed Abstract available

LI S, Zhou B, Xue M, Zhu J, et al
Macrophage-specific FGF12 promotes liver fibrosis progression in mice.
Hepatology. 2023;77:816-833.
PubMed Abstract available

February 2023

ZANETTO A, Campello E, Senzolo M, Simioni P, et al
The evolving knowledge on primary hemostasis in patients with cirrhosis: A comprehensive review.
Hepatology. 2023 Feb 27. doi: 10.1097/HEP.0000000000000349.
PubMed Abstract available

DU K, Maeso-Diaz R, Oh SH, Wang E, et al
Targeting YAP-mediated hepatic stellate cell death susceptibility and senescence for treatment of liver fibrosis.
Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000326.
PubMed Abstract available

NICOARA-FARCAU O, Lozano JJ, Alonso C, Sidorova J, et al
Metabolomics as a tool to predict the risk of decompensation or liver related death in patients with compensated cirrhosis.
Hepatology. 2023 Feb 23. doi: 10.1097/HEP.0000000000000316.
PubMed Abstract available

GAWRIEH S, Lake JE, Debroy P, Sjoquist JA, et al
Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study.
Hepatology. 2023 Feb 22. doi: 10.1097/HEP.0000000000000313.
PubMed Abstract available

Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis: Erratum.
Hepatology. 2023 Feb 21. doi: 10.1097/HEP.0000000000000348.
PubMed

WU N, Zhou T, Carpino G, Baiocchi L, et al
Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2-/- mice.
Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000310.
PubMed Abstract available

ZHANG J, Lyu Z, Li B, You Z, et al
P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.
Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000317.
PubMed Abstract available

LIN H, Yip TC, Zhang X, Li G, et al
Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease.
Hepatology. 2023;77:573-584.
PubMed Abstract available

VAN KLEEF LA, Sonneveld MJ, Kavousi M, Ikram MA, et al
Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study.
Hepatology. 2023;77:585-593.
PubMed Abstract available

INDIRA CHANDRAN V, Wernberg CW, Lauridsen MM, Skytthe MK, et al
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness.
Hepatology. 2023;77:558-572.
PubMed Abstract available

January 2023

ADEJUMO AC, Yakovchenko V, Morgan TR, Spoutz P, et al
The road to pandemic recovery: Tracking COVID-19's impact on cirrhosis care and outcomes among 111,558 veterans.
Hepatology. 2023 Jan 30. doi: 10.1097/HEP.0000000000000306.
PubMed Abstract available

HUANG DQ, Tamaki N, Lee HW, Park SY, et al
Outcome of untreated low-level viremia vs. antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis.
Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000037.
PubMed Abstract available

CASTERA L, Cusi K
Diabetes and cirrhosis: Current concepts on diagnosis and management.
Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000263.
PubMed Abstract available

GUILLOT A, Winkler M, Silva Afonso M, Aggarwal A, et al
Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression.
Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000270.
PubMed Abstract available

ALLAIRE M, Thabut D
Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management.
Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000291.
PubMed Abstract available

BHALA N, Ferguson JW, Rajoriya N, Newsome PN, et al
Using global burden of hepatocellular cancer and liver cirrhosis as a driver to tackle preventable mortality and morbidity nationally and regionally.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000011.
PubMed

FENG Y, Peng B, Li Y, Sun L, et al
Letter to the editor: diagnosing fibrosis and cirrhosis in nonalcoholic fatty liver disease using machine learning models.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000209.
PubMed

CHANG D, Truong E, Noureddin M
Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: Accuracy and routine variables are the success keys.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000211.
PubMed

SHARPTON SR, Loomba R
Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000278.
PubMed Abstract available

TANTAI X, Wang J, Dai S
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000271.
PubMed

MA F, Liu Y, Hu Z, Xue Y, et al
Intrahepatic osteopontin signaling by CREBZF defines a checkpoint for steatosis-to-NASH progression.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000042.
PubMed Abstract available

GONG L, Wei F, Gonzalez FJ, Li G, et al
Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000182.
PubMed Abstract available

SEMMLER G, Thorhauge KH, Reiberger T, Thiele M, et al
Letter to the editor: Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD.
Hepatology. 2023;77:E1-E2.
PubMed

GIDENER T, Dierkhising RA, Mara KC, Therneau TM, et al
Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD.
Hepatology. 2023;77:268-274.
PubMed Abstract available

HAGSTROM H
A new model for estimation of significant fibrosis in primary care. SAFE to use?
Hepatology. 2023;77:18-19.
PubMed

SRIPONGPUN P, Kim WR, Mannalithara A, Charu V, et al
The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care.
Hepatology. 2023;77:256-267.
PubMed Abstract available

December 2022

RATZIU V, Anstee QM, Wong VW, Schattenberg JM, et al
An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT project.
Hepatology. 2022;76:1766-1777.
PubMed Abstract available

November 2022

ZHANG X, Wong GL, Yip TC, Cheung JTK, et al
Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease.
Hepatology. 2022;76:1409-1422.
PubMed Abstract available

LEI L, Bruneau A, El Mourabit H, Guegan J, et al
Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis.
Hepatology. 2022;76:1360-1375.
PubMed Abstract available

October 2022

BALOG S, Fujiwara R, Pan SQ, El-Baradie KB, et al
Emergence of highly profibrotic and proinflammatory Lrat(+) Fbln2(+) hepatic stellate cell subpopulation in alcoholic hepatitis.
Hepatology. 2022 Oct 1. doi: 10.1002/hep.32793.
PubMed Abstract available

September 2022

VIZZUTTI F, Celsa C, Battaglia S, Miraglia R, et al
Reply to the Letter to the Editor: "Predicting mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis - does novelty supplant the standard?"
Hepatology. 2022 Sep 30. doi: 10.1002/hep.32813.
PubMed

VAZ K, Little R, Majeed A, Roberts S, et al
Letter to the Editor: Predicting mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis - does novelty supplant the standard?
Hepatology. 2022 Sep 28. doi: 10.1002/hep.32811.
PubMed

ALLEGRETTI AS
NGAL in AKI and cirrhosis - ready for prime time?
Hepatology. 2022 Sep 28. doi: 10.1002/hep.32807.
PubMed

MAK LY, Hui RW, Lee CH, Mao X, et al
Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes.
Hepatology. 2022 Sep 21. doi: 10.1002/hep.32716.
PubMed Abstract available

GAMBINO C, Piano S, Stenico M, Tonon M, et al
Diagnostic and prognostic performance of urinary Neutrophil Gelatinase-associated Lipocalin in patients with cirrhosis and AKI.
Hepatology. 2022 Sep 20. doi: 10.1002/hep.32799.
PubMed Abstract available

MAO X, Cheung KS, Peng C, Mak LY, et al
Steatosis, HBV-related hepatocellular carcinoma, cirrhosis & HBsAg seroclearance: a systematic review and meta-analysis.
Hepatology. 2022 Sep 15. doi: 10.1002/hep.32792.
PubMed Abstract available

LIU Y, Zhang J, Xu Y, Lu X, et al
Letter to the editor: Reflection on the unsatisfactory model predicting mortality after TIPS in cirrhotic patients.
Hepatology. 2022 Sep 14. doi: 10.1002/hep.32785.
PubMed

VIZZUTTI F, Celsa C, Battaglia S, Miraglia R, et al
Reply to the Letter to the Editor: "Reflection on the unsatisfactory model predicting mortality after TIPS in cirrhotic patients".
Hepatology. 2022 Sep 13. doi: 10.1002/hep.32784.
PubMed

LEUNG DH, Devaraj S, Goodrich NP, Chen X, et al
Serum Biomarkers Correlated with Liver Stiffness Assessed in a Multi-center Study of Pediatric Cholestatic Liver Disease.
Hepatology. 2022 Sep 7. doi: 10.1002/hep.32777.
PubMed Abstract available

DUAN Z
Postvaccination COVID-19 related mortality in patients with cirrhosis:who is the culprit?
Hepatology. 2022 Sep 5. doi: 10.1002/hep.32750.
PubMed

KNORR J, Kaufmann B, Inzaugarat ME, Holtmann TM, et al
Interleukin-18 signaling promotes activation of hepatic stellate cells in murine liver fibrosis.
Hepatology. 2022 Sep 4. doi: 10.1002/hep.32776.
PubMed Abstract available

HARRIS EN
Will inhibition of cellular crosstalk resolve liver fibrosis?
Hepatology. 2022;76:558-560.
PubMed

LIN Y, Dong MQ, Liu ZM, Xu M, et al
A strategy of vascular-targeted therapy for liver fibrosis.
Hepatology. 2022;76:660-675.
PubMed Abstract available

August 2022

LUO W, Wang Y, Li Y, Zhang T, et al
Letter to the editor: Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS.
Hepatology. 2022 Aug 25. doi: 10.1002/hep.32755.
PubMed

JOHN BV, Dahman B
COVID-19 related mortality in Cirrhosis is not associated with Proton Pump Inhibitor Exposure.
Hepatology. 2022 Aug 24. doi: 10.1002/hep.32748.
PubMed

LO GH
Could COVID-19 vaccination reduce post-infection mortality in most cirrhotic patients ?
Hepatology. 2022 Aug 24. doi: 10.1002/hep.32751.
PubMed

JOHN BV, Dahman B
COVID-19 Vaccination and mortality in Decompensated Cirrhosis.
Hepatology. 2022 Aug 24. doi: 10.1002/hep.32749.
PubMed

SERPER M, Kaplan DE, Taddei TH, Tapper EB, et al
Non-selective Beta Blockers, Hepatic Decompensation and Mortality in Cirrhosis: A National Cohort Study.
Hepatology. 2022 Aug 19. doi: 10.1002/hep.32737.
PubMed Abstract available

LOUREIRO D, Tout I, Narguet S, Bed CM, et al
Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C or nonalcoholic steatohepatitis.
Hepatology. 2022 Aug 16. doi: 10.1002/hep.32731.
PubMed Abstract available

VIZZUTTI F, Celsa C, Calvaruso V, Enea M, et al
Mortality after transjugular intrahepatic portosystemic shunt in older adult cirrhotic patients: a validated prediction model.
Hepatology. 2022 Aug 3. doi: 10.1002/hep.32704.
PubMed Abstract available

PATTOU F, Lasailly G, Raverdy V, Caiazzo R, et al
Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two-third full rather than half empty.
Hepatology. 2022;76:E51-E52.
PubMed

JINDAL A
Letter to the editor: Liver outcomes after bariatric surgery in patients with NASH and advanced fibrosis.
Hepatology. 2022;76:E42.
PubMed

GUIDOTTI LG, La Vecchia C, Colombo M
Low-dose aspirin reduces the risk of HBV-associated HCC even when administered short-term: Too good to be true?
Hepatology. 2022;76:300-302.
PubMed

MAYO MJ
Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
Hepatology. 2022;76:518-531.
PubMed Abstract available

VALAINATHAN SR, Sartoris R, Elkrief L, Magaz M, et al
Contrast-enhanced CT and liver surface nodularity for the diagnosis of porto-sinusoidal vascular disorder: A case-control study.
Hepatology. 2022;76:418-428.
PubMed Abstract available

PAIS R, Aron-Wisnewsky J, Bedossa P, Ponnaiah M, et al
Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery.
Hepatology. 2022;76:456-468.
PubMed Abstract available

GUNEWARDENA S, Huck I, Walesky C, Robarts D, et al
Progressive loss of hepatocyte nuclear factor 4 alpha activity in chronic liver diseases in humans.
Hepatology. 2022;76:372-386.
PubMed Abstract available

ZHANG X, Wang Z, Tang W, Wang X, et al
Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.
Hepatology. 2022;76:317-329.
PubMed Abstract available

ZHANG X, Wong GL, Yip TC, Tse YK, et al
Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease.
Hepatology. 2022;76:469-482.
PubMed Abstract available

July 2022

QUECK A, Schwierz L, Gu W, Ferstl PG, et al
Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS.
Hepatology. 2022 Jul 23. doi: 10.1002/hep.32676.
PubMed Abstract available

LIU X, Tan S, Liu H, Jiang J, et al
Hepatocyte-derived MASP1-enriched small extracellular vesicles activate hepatic stellate cells to promote liver fibrosis.
Hepatology. 2022 Jul 18. doi: 10.1002/hep.32662.
PubMed Abstract available

BITTERMANN T, Lewis JD, Levy C, Goldberg DS, et al
Sociodemographic and geographic differences in the U.S. epidemiology of autoimmune hepatitis with and without cirrhosis.
Hepatology. 2022 Jul 10. doi: 10.1002/hep.32653.
PubMed Abstract available

CHANG D, Truong E, Mena EA, Pacheco F, et al
Machine Learning Models Are Superior to Non-Invasive Tests in Identifying Clinically Significant Stages of NAFLD and NAFLD-Related Cirrhosis.
Hepatology. 2022 Jul 9. doi: 10.1002/hep.32655.
PubMed Abstract available

KAWAMURA N, Imajo K, Kalutkiewicz KJ, Nagai K, et al
Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
Hepatology. 2022;76:186-195.
PubMed Abstract available

DEVARAJ E, Perumal E, Subramaniyan R, Mustapha N, et al
Liver fibrosis: Extracellular vesicles mediated intercellular communication in perisinusoidal space.
Hepatology. 2022;76:275-285.
PubMed

June 2022

JOHN BV, Doshi A, Ferreira RD, Taddei TH, et al
Comparison of Infection-induced and Vaccine-induced Immunity Against Coronavirus 2019 in Patients with Cirrhosis.
Hepatology. 2022 Jun 16. doi: 10.1002/hep.32619.
PubMed Abstract available

XU J, Wang Y, Khoshdeli M, Peach M, et al
IL-31 Levels Correlate with Pruritus in Patients with Cholestatic and Metabolic Liver Diseases and is FXR Responsive in NASH.
Hepatology. 2022 Jun 10. doi: 10.1002/hep.32599.
PubMed Abstract available

HOLMAN A, Parikh N, Clauw DJ, Williams DA, et al
Rethinking the management of pain in cirrhosis: toward precision therapy for pain.
Hepatology. 2022 Jun 5. doi: 10.1002/hep.32598.
PubMed Abstract available

DELTENRE P, Zanetto A, Saltini D, Moreno C, et al
The role of TIPS in patients with cirrhosis and ascites: recent evolution and open questions.
Hepatology. 2022 Jun 4. doi: 10.1002/hep.32596.
PubMed Abstract available

JULIEN J, Ayer T, Tapper EB, Barbosa C, et al
Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: A modeling study.
Hepatology. 2022;75:1480-1490.
PubMed Abstract available

May 2022

HARRINGTON C, Krishnan S, Mack CL, Cravedi P, et al
Non-Invasive Biomarkers for the Diagnosis and Management of Autoimmune Hepatitis.
Hepatology. 2022 May 25. doi: 10.1002/hep.32591.
PubMed Abstract available

KIMURA Y, Koyama Y, Taura K, Kudoh A, et al
Characterization and role of collagen gene expressing hepatic cells following partial hepatectomy in mice.
Hepatology. 2022 May 23. doi: 10.1002/hep.32586.
PubMed Abstract available

PILLING LC, Atkins JL, Melzer D
Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: associations in a large community cohort.
Hepatology. 2022 May 14. doi: 10.1002/hep.32575.
PubMed Abstract available

BAJAJ JS, Rodriguez MP, Fagan A, McGeorge S, et al
Impact of Bacterial Infections and SBP Prophylaxis on Phage-Bacterial Dynamics in Cirrhosis.
Hepatology. 2022 May 13. doi: 10.1002/hep.32571.
PubMed Abstract available

SMIRNOVA E, Muthiah MD, Narayan N, Siddiqui MS, et al
Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
Hepatology. 2022 May 13. doi: 10.1002/hep.32568.
PubMed Abstract available

MEHTA S, Asrani SK
The computer will see you now: Prediction of long-term survival in patients with cirrhosis.
Hepatology. 2022 May 5. doi: 10.1002/hep.32559.
PubMed

GULATI P, Taneja S, Duseja A, Singh V, et al
Letter to Editor-Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study- Should we extend the boundaries?
Hepatology. 2022 May 3. doi: 10.1002/hep.32554.
PubMed

HILSCHER MB, Wells ML, Venkatesh SK, Cetta F, et al
Fontan-associated liver disease.
Hepatology. 2022;75:1300-1321.
PubMed

April 2022

SHAH PA, Patil R, Harrison SA
NAFLD-related hepatocellular carcinoma: The growing challenge.
Hepatology. 2022 Apr 28. doi: 10.1002/hep.32542.
PubMed Abstract available

ZHOU Y, Chu W, Wu X, Zhou H, et al
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
Hepatology. 2022 Apr 2. doi: 10.1002/hep.32504.
PubMed

SINGH SA, Madan K, Gupta S, Indrayan A, et al
Letter to the editor: Relevance of population-based cutoffs to define frailty in clinical studies.
Hepatology. 2022;75:1067-1068.
PubMed

WANG S, Whitlock R, Lai JC, Taneja S, et al
Reply.
Hepatology. 2022;75:1068-1069.
PubMed

COLASANTI T, Di Giamberardino A, Grimaldi A, Cardinale V, et al
Letter to the editor: Serum thrombospondin-2 as biomarker in liver diseases, a look beyond NASH.
Hepatology. 2022;75:1056-1057.
PubMed

KWAN SY, Jiao J, Joon A, Wei P, et al
Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease.
Hepatology. 2022;75:955-967.
PubMed Abstract available

SUBRAMANIAN P, Gargani S, Palladini A, Chatzimike M, et al
The RNA binding protein human antigen R is a gatekeeper of liver homeostasis.
Hepatology. 2022;75:881-897.
PubMed Abstract available

March 2022

CULLARO G, Hsu CY, Lai JC
Variability in Serum Creatinine is Associated with Waitlist and Post-Liver Transplant Mortality in Cirrhosis Patients.
Hepatology. 2022 Mar 31. doi: 10.1002/hep.32497.
PubMed Abstract available

D'ALESSIO A, Fulgenzi CAM, Nishida N, Schonlein M, et al
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study.
Hepatology. 2022 Mar 21. doi: 10.1002/hep.32468.
PubMed Abstract available

FLEMMING JA, Muaddi H, Djerboua M, Neves P, et al
Association between social determinants of health and rates of liver transplantation in individuals with cirrhosis.
Hepatology. 2022 Mar 21. doi: 10.1002/hep.32469.
PubMed Abstract available

CREEDEN JF, Kipp ZA, Xu M, Flight RM, et al
Hepatic Kinome Atlas: An In-Depth Identification of Kinase Pathways in Liver Fibrosis of Humans and Rodents.
Hepatology. 2022 Mar 21. doi: 10.1002/hep.32467.
PubMed Abstract available

GOLDBERG D, Mantero A, Kaplan D, Delgado C, et al
Accurate Long-Term Prediction of Death for Patients with Cirrhosis.
Hepatology. 2022 Mar 12. doi: 10.1002/hep.32457.
PubMed Abstract available

HE Q, Zhang F, Shu J, Li S, et al
Immunocompromised rabbit model of chronic hepatitis E reveals liver fibrosis and distinct efficacy of different vaccination strategies.
Hepatology. 2022 Mar 12. doi: 10.1002/hep.32455.
PubMed Abstract available

LV Y, Chen H, Luo B, Bai W, et al
Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A randomized controlled trial.
Hepatology. 2022 Mar 10. doi: 10.1002/hep.32453.
PubMed Abstract available

BEKKI Y, Fenig Y
Letter to the editor: The impact of donor liver fibrosis on early allograft dysfunction and ischemia-reperfusion injury.
Hepatology. 2022;75:754.
PubMed

KANWAL F, Khaderi S, Singal AG, Marrero JA, et al
Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis.
Hepatology. 2022 Mar 1. doi: 10.1002/hep.32434.
PubMed Abstract available

TAMAKI N, Imajo K, Sharpton S, Jung J, et al
Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.
Hepatology. 2022;75:661-672.
PubMed Abstract available

February 2022

D'AMBROSIO R, Lampertico P
Is it time to refine HCC surveillance strategies in HCV cured patients?
Hepatology. 2022 Feb 26. doi: 10.1002/hep.32430.
PubMed

ROBERTS SB, Hirschfield GM, Worobetz LJ, Vincent C, et al
Ethnicity, disease severity and survival in Canadian patients with Primary Biliary Cholangitis.
Hepatology. 2022 Feb 26. doi: 10.1002/hep.32426.
PubMed Abstract available

NOUREDDIN M, Abdelmalek MF
ACE inhibitors: The Secret to Prevent Cirrhosis Complications and Hepatocellular Carcinoma in NAFLD?
Hepatology. 2022 Feb 6. doi: 10.1002/hep.32399.
PubMed

YAKOVCHENKO V, Morgan TR, Miech EJ, Neely B, et al
Core implementation strategies for improving cirrhosis care in the Veterans Health Administration.
Hepatology. 2022 Feb 6. doi: 10.1002/hep.32395.
PubMed Abstract available

ZANETTO A, Campello E, Spiezia L, Burra P, et al
Letter to the Editor: is PAI-1 a thrombotic biomarker in NASH cirrhosis?
Hepatology. 2022 Feb 3. doi: 10.1002/hep.32392.
PubMed

INDOLFI G, Kelly D, Nebbia G, Iorio R, et al
Sofosbuvir-Velpatasvir-Voxilaprevir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Infection.
Hepatology. 2022 Feb 3. doi: 10.1002/hep.32393.
PubMed Abstract available

LEMOINE CP, Superina R
Letter to the Editor: Is TIPS the best treatment for non-cirrhotic adults with EPHVO and portal hypertension?
Hepatology. 2022 Feb 2. doi: 10.1002/hep.32386.
PubMed

ROGAL S, Hansen L, Patel A, Ufere NN, et al
AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis.
Hepatology. 2022 Feb 1. doi: 10.1002/hep.32378.
PubMed

YANG Y, Choi J, Chen Y, Invernizzi P, et al
E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants.
Hepatology. 2022;75:266-279.
PubMed Abstract available

GIDENER T, Yin M, Dierkhising RA, Allen AM, et al
Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: A retrospective study.
Hepatology. 2022;75:379-390.
PubMed Abstract available

VAN KLEEF LA, Ayada I, Alferink LJM, Pan Q, et al
Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
Hepatology. 2022;75:419-429.
PubMed Abstract available

January 2022

DE A, Keisham A, Duseja A
Spontaneous regression of cirrhosis: a paradigm shift in our understanding of the natural history of non-alcoholic steatohepatitis (NASH).
Hepatology. 2022 Jan 31. doi: 10.1002/hep.32374.
PubMed

JANG H, Lee YB, Moon H, Chung JW, et al
Aspirin Use and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B With or Without Cirrhosis.
Hepatology. 2022 Jan 31. doi: 10.1002/hep.32380.
PubMed Abstract available

KUMAR A, Sharma P, Arora A
Letter to the Editor: In patients with established NASH cirrhosis, is there no role of weight reduction in reversing fibrosis?
Hepatology. 2022 Jan 29. doi: 10.1002/hep.32375.
PubMed

LOCKART I, Yeo MGH, Hajarizadeh B, Dore GJ, et al
Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.
Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341.
PubMed Abstract available

JOHN BV, Deng Y, Schwartz KB, Taddei TH, et al
Post-Vaccination COVID-19 Infection is Associated with Reduced Mortality in Patients With Cirrhosis.
Hepatology. 2022 Jan 12. doi: 10.1002/hep.32337.
PubMed Abstract available

FANG ZQ, Ruan B, Liu JJ, Duan JL, et al
Notch-triggered maladaptation of liver sinusoidal endothelium aggravates nonalcoholic steatohepatitis through eNOS.
Hepatology. 2022 Jan 10. doi: 10.1002/hep.32332.
PubMed Abstract available

NG CH, Xiao J, Lim WH, Chin YH, et al
Placebo Effect on Progression and Regression in Non-Alcoholic Steatohepatitis. Evidence from a Meta-Analysis.
Hepatology. 2022 Jan 6. doi: 10.1002/hep.32315.
PubMed Abstract available

GINES P, Castera L, Lammert F, Graupera I, et al
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases.
Hepatology. 2022;75:219-228.
PubMed Abstract available

December 2021

RIDOLA L, Nardelli S, Gioia S, Faccioli J, et al
Letter to the editor: Episodic-precipitant induced hepatic encephalopathy treatment: look at new and old precipitants!
Hepatology. 2021 Dec 24. doi: 10.1002/hep.32306.
PubMed

KODAMA T, Takehara T
Reply; Transcriptomics identify thrombospondin-2 as a biomarker for nonalcoholic steatohepatitis and advanced liver fibrosis.
Hepatology. 2021 Dec 20. doi: 10.1002/hep.32292.
PubMed

FRIEDMAN SL, Pinzani M
Hepatic Fibrosis 2022: Unmet Needs and a Blueprint for the Future.
Hepatology. 2021 Dec 19. doi: 10.1002/hep.32285.
PubMed Abstract available

LIBRERO JIMENEZ M, Lopez Garrido MA, Fernandez Cano MC
Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis.
Hepatology. 2021 Dec 8. doi: 10.1002/hep.32271.
PubMed

KAWAI H, Osawa Y, Matsuda M, Tsunoda T, et al
Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy.
Hepatology. 2021 Dec 2. doi: 10.1002/hep.32256.
PubMed Abstract available

BAI W, Al-Karaghouli M, Stach J, Sung S, et al
Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials.
Hepatology. 2021;74:3301-3315.
PubMed Abstract available

November 2021

JAIN A, Sharma BC, Mahajan B, Srivastava S, et al
"L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial".
Hepatology. 2021 Nov 25. doi: 10.1002/hep.32255.
PubMed Abstract available

POLITI J, Guerras JM, Donat M, Belza MJ, et al
Favorable impact in Hepatitis C related mortality following free-access to direct-acting antivirals in Spain.
Hepatology. 2021 Nov 12. doi: 10.1002/hep.32237.
PubMed Abstract available

KIM ER, Park JS, Kim JH, Oh JY, et al
A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome.
Hepatology. 2021 Nov 12. doi: 10.1002/hep.32235.
PubMed Abstract available

WU N, Carpino G, Ceci L, Baiocchi L, et al
MT1 but not MT2 melatonin receptor knockout decreases biliary damage and liver fibrosis during cholestatic liver injury.
Hepatology. 2021 Nov 7. doi: 10.1002/hep.32233.
PubMed Abstract available

OTERO SANCHEZ L, Karakike E, Njimi H, Putignano A, et al
Clinical Course and Risk Factors for Infection in Severe Forms of Alcohol-Associated Liver Disease.
Hepatology. 2021;74:2714-2724.
PubMed Abstract available

KNIGHT GM, Clark J, Boike JR, Maddur H, et al
TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard-of-Care Therapy.
Hepatology. 2021;74:2735-2744.
PubMed Abstract available

SIMON TG, Roelstraete B, Sharma R, Khalili H, et al
Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
Hepatology. 2021;74:2410-2423.
PubMed Abstract available

JAGDISH RK, Maras JS, Sarin SK
Albumin in Advanced Liver Diseases: The Good and Bad of a Drug!
Hepatology. 2021;74:2848-2862.
PubMed Abstract available

October 2021

KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
PubMed Abstract available

LAN T, Jiang S, Zhang J, Weng Q, et al
Breviscapine Alleviates Nonalcoholic Steatohepatitis by Inhibiting TGF-beta-activated Kinase 1-dependent Signaling.
Hepatology. 2021 Oct 30. doi: 10.1002/hep.32221.
PubMed Abstract available

MANCUSO A
Portal vein thrombosis in cirrhosis: the issue of treatment.
Hepatology. 2021 Oct 28. doi: 10.1002/hep.32216.
PubMed Abstract available

SANYAL AJ, Anstee QM, Trauner M, Lawitz EJ, et al
Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.
Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.
PubMed Abstract available

SINGAL AG, Nabihah T, Mehta A, Marrero JA, et al
GALAD Demonstrates High Sensitivity for HCC Surveillance in a Cohort of Patients with Cirrhosis.
Hepatology. 2021 Oct 7. doi: 10.1002/hep.32185.
PubMed Abstract available

LAWITZ EJ, Shevell DE, Tirucherai GS, Du S, et al
BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
PubMed Abstract available

EDELSON JC, Rockey DC
Letter to the Editor: Complications Associated With Anesthesia Services in Endoscopic Procedures Among Patients With Cirrhosis.
Hepatology. 2021;74:2313-2314.
PubMed

LLEO A, Hirschfield GM
Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?
Hepatology. 2021;74:2307.
PubMed

WALTER A, Rudler M, Olivas P, Moga L, et al
Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding.
Hepatology. 2021;74:2085-2101.
PubMed Abstract available

COLUCCI S, Altamura S, Marques O, Dropmann A, et al
Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFbeta Pathway Activation.
Hepatology. 2021;74:2186-2200.
PubMed Abstract available

CHOI WM, Ryu T, Lee JH, Shim YR, et al
Metabotropic Glutamate Receptor 5 in Natural Killer Cells Attenuates Liver Fibrosis by Exerting Cytotoxicity to Activated Stellate Cells.
Hepatology. 2021;74:2170-2185.
PubMed Abstract available

DINANI AM, Kowdley KV, Noureddin M
Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art.
Hepatology. 2021;74:2233-2240.
PubMed Abstract available

LUO X, Xiang T, Wu J, Wang X, et al
Endoscopic Cyanoacrylate Injection Versus Balloon-Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Bleeding: A Randomized Controlled Trial.
Hepatology. 2021;74:2074-2084.
PubMed Abstract available

September 2021

GARCIA-TSAO G
Can we rely on changes in HVPG in patients with cirrhosis?
Hepatology. 2021 Sep 27. doi: 10.1002/hep.32159.
PubMed Abstract available

DRIEVER EG, von Meijenfeldt FA, Adelmeijer J, de Haas RJ, et al
Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.
Hepatology. 2021 Sep 24. doi: 10.1002/hep.32169.
PubMed Abstract available

WANG S, Whitlock R, Xu C, Taneja S, et al
Frailty is associated with increased risk of cirrhosis disease progression and death.
Hepatology. 2021 Sep 15. doi: 10.1002/hep.32157.
PubMed Abstract available

ZHANG X, Yang H, Zeng S, Tian S, et al
Melanoma-Differentiation-Associated gene 5 protects against nonalcoholic steatohepatitis in mice.
Hepatology. 2021 Sep 5. doi: 10.1002/hep.32139.
PubMed Abstract available

RAEVENS S, Boret M, De Pauw M, Fallon MB, et al
Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome.
Hepatology. 2021;74:1674-1686.
PubMed Abstract available

WANG SS, Tang XT, Lin M, Yuan J, et al
Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer-Associated Fibroblasts Formed After Chronic Liver Injuries.
Hepatology. 2021;74:1578-1594.
PubMed Abstract available

STARLINGER P, Ahn JC, Mullan A, Gyoeri GP, et al
The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.
Hepatology. 2021;74:1533-1545.
PubMed Abstract available

LIU Y, Song J, Yang J, Zheng J, et al
Tumor Necrosis Factor alpha-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation.
Hepatology. 2021;74:1300-1318.
PubMed Abstract available

August 2021

INNES H, Crooks CJ, Aspinall E, Card TR, et al
Characterising the risk interplay between alcohol intake and body mass index on cirrhosis morbidity.
Hepatology. 2021 Aug 28. doi: 10.1002/hep.32123.
PubMed Abstract available

LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.
Hepatology. 2021 Aug 24. doi: 10.1002/hep.32117.
PubMed Abstract available

ALLAIRE M, Garcia-Pagan JC, Walter A, Bureau C, et al
Salvage TIPS in cirrhotic patients with variceal bleeding: MELD, lactates and << a la carte >> decision.
Hepatology. 2021 Aug 5. doi: 10.1002/hep.32091.
PubMed Abstract available

BOSCH J, Chung C, Carrasco-Zevallos OM, Harrison SA, et al
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087.
PubMed Abstract available

SAVIANO A, Wrensch F, Ghany MG, Baumert TF, et al
Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care.
Hepatology. 2021;74:1088-1100.
PubMed Abstract available

CARTER J, Wang S, Friedman SL
Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis.
Hepatology. 2021;74:543-546.
PubMed

LIANG YJ, Teng W, Chen CL, Sun CP, et al
Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.
Hepatology. 2021;74:641-655.
PubMed Abstract available

TRIANTOS C, Aggeletopoulou I, Thomopoulos K, Mouzaki A, et al
Vitamin D-Liver Disease Association: Biological Basis and Mechanisms of Action.
Hepatology. 2021;74:1065-1073.
PubMed

July 2021

WIN S, Min RWM, Zhang J, Kanel G, et al
Hepatic mitochondrial SAB deletion or knockdown alleviates diet induced metabolic syndrome, steatohepatitis and hepatic fibrosis.
Hepatology. 2021 Jul 31. doi: 10.1002/hep.32083.
PubMed Abstract available

PIANO S, Cardenas A
Metabolomics to predict acute kidney injury in cirrhosis.
Hepatology. 2021 Jul 16. doi: 10.1002/hep.32060.
PubMed Abstract available

LAI JC, Tandon P, Bernal W, Tapper EB, et al
Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
Hepatology. 2021 Jul 7. doi: 10.1002/hep.32049.
PubMed Abstract available

CAPORALI C, Turco L, Prampolini F, Quaretti P, et al
Proximal splenic artery embolization to treat refractory ascites in a cirrhotic patient.
Hepatology. 2021 Jul 4. doi: 10.1002/hep.32037.
PubMed Abstract available

TAYLOR-WEINER A, Pokkalla H, Han L, Jia C, et al
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.
Hepatology. 2021;74:133-147.
PubMed Abstract available

KENNEDY L, Meadows V, Sybenga A, Demieville J, et al
Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet.
Hepatology. 2021;74:164-182.
PubMed Abstract available

HOU X, Yin S, Ren R, Liu S, et al
Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis.
Hepatology. 2021;74:116-132.
PubMed Abstract available

POSE E, Coll M, Martinez-Sanchez C, Zeng Z, et al
Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections.
Hepatology. 2021;74:296-311.
PubMed Abstract available

June 2021

FLEMMING JA, Djerboua M, Groome PA, Booth CM, et al
NAFLD and alcohol-related liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040.
Hepatology. 2021 Jun 26. doi: 10.1002/hep.32032.
PubMed Abstract available

HIRAO H, Ito T, Kadono K, Kojima H, et al
Donor Hepatic Occult Collagen Deposition Predisposes to Peri-transplant Stress and Impacts Human Liver Transplantation.
Hepatology. 2021 Jun 25. doi: 10.1002/hep.32030.
PubMed Abstract available

LIU H, Lee SS
Diagnostic criteria of cirrhotic cardiomyopathy: out with the old, in with the new?
Hepatology. 2021 Jun 21. doi: 10.1002/hep.32021.
PubMed Abstract available

JEPSEN P, Tapper EB, Deleuran T, Kazankov K, et al
Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nationwide cohort study.
Hepatology. 2021 Jun 16. doi: 10.1002/hep.32019.
PubMed Abstract available

SHI YF, Xie WZ
Letter to the Editor: Risk Stratification in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
Hepatology. 2021 Jun 15. doi: 10.1002/hep.32013.
PubMed Abstract available

MAZUMDER NR, Simpson D, Atiemo K, Jackson K, et al
Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study.
Hepatology. 2021 Jun 15. doi: 10.1002/hep.31742.
PubMed Abstract available

BARRON-MILLAR B, Ogle L, Mells G, Flack S, et al
The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
Hepatology. 2021 Jun 15. doi: 10.1002/hep.32011.
PubMed Abstract available

JINDAL A, Sharma S
Biomarkers for predicting renal outcomes in decompensated cirrhosis - Need a closer look!
Hepatology. 2021 Jun 9. doi: 10.1002/hep.32005.
PubMed Abstract available

KOZUMI K, Kodama T, Murai H, Sakane S, et al
Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis.
Hepatology. 2021 Jun 9. doi: 10.1002/hep.31995.
PubMed Abstract available

YANG W, He H, Wang T, Su N, et al
Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis.
Hepatology. 2021 Jun 5. doi: 10.1002/hep.31987.
PubMed Abstract available

VUPPALANCHI R, Loomba R
Noninvasive Tests to Phenotype Nonalcoholic Fatty Liver Disease: Sequence and Consequences of Arranging the Tools in the Tool Box.
Hepatology. 2021;73:2095-2098.
PubMed

CASSINOTTO C, Boursier J, Paisant A, Guiu B, et al
Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD.
Hepatology. 2021;73:2196-2205.
PubMed Abstract available

CHOI J, Yoo S, Lim YS
Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance.
Hepatology. 2021;73:2155-2166.
PubMed Abstract available

CHO YE, Kim DK, Seo W, Gao B, et al
Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol-Inducible Cytochrome P450-2E1-Mediated Oxidative and Nitrative Stress.
Hepatology. 2021;73:2180-2195.
PubMed Abstract available

KYRITSI K, Kennedy L, Meadows V, Hargrove L, et al
Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
Hepatology. 2021;73:2397-2410.
PubMed Abstract available

May 2021

SUN LY, Hu JY, Liang L, Tong XM, et al
Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
PubMed Abstract available

JOHN BV, Deng Y, Martin P, Levy C, et al
Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
PubMed Abstract available

MEHTA G, Jalan R
The 'Alter Ego' of Albumin in Cirrhosis.
Hepatology. 2021 May 18. doi: 10.1002/hep.31908.
PubMed Abstract available

BAJAJ JS, Garcia-Tsao G, Reddy KR, O'Leary JG, et al
Admission urinary and serum metabolites predict renal outcomes in hospitalized patients with cirrhosis.
Hepatology. 2021 May 18. doi: 10.1002/hep.31907.
PubMed Abstract available

MESZAROS M, Truchi R, Ouzan D, Tran A, et al
Sofosbuvir, glecaprevir, pibrentasvir, and ribavirin as a rescue therapy in difficult-to-treat hepatitis C patients.
Hepatology. 2021 May 18. doi: 10.1002/hep.31909.
PubMed Abstract available

VALSAN A, Verma N, Singh V
Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!
Hepatology. 2021 May 11. doi: 10.1002/hep.31896.
PubMed Abstract available

ELKRIEF L, Lazareth M, Rautou PE
Reply to: "Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!"
Hepatology. 2021 May 11. doi: 10.1002/hep.31894.
PubMed Abstract available

DICHTEL LE
The GLP-1 Receptor Agonist Semaglutide for the Treatment of Nonalcoholic Steatohepatitis.
Hepatology. 2021 May 6. doi: 10.1002/hep.31886.
PubMed Abstract available

April 2021

ISHIKAWA T, Sasaki R, Matsuda T, Saeki I, et al
Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension.
Hepatology. 2021 Apr 26. doi: 10.1002/hep.31865.
PubMed Abstract available

SONG Z, Chen W, Athavale D, Ge X, et al
Osteopontin Takes Center Stage in Chronic Liver Disease.
Hepatology. 2021;73:1594-1608.
PubMed Abstract available

CHEN L, Guo P, Li W, Fang F, et al
Perturbation of Specific Signaling Pathways Is Involved in Initiation of Mouse Liver Fibrosis.
Hepatology. 2021;73:1551-1569.
PubMed Abstract available

March 2021

YASUDO H, Ando T, Maehara A, Ando T, et al
A possible association between a novel NLRP1 mutation and an autoinflammatory disease involving liver cirrhosis.
Hepatology. 2021 Mar 19. doi: 10.1002/hep.31818.
PubMed Abstract available

CRISTOFERI L, Calvaruso V, Overi D, Vigano M, et al
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naive patients with Primary Biliary Cholangitis: a dual cut-off approach.
Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810.
PubMed Abstract available

ALEXOPOULOS AS, Crowley MJ, Wang Y, Moylan CA, et al
Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.
Hepatology. 2021 Mar 16. doi: 10.1002/hep.31806.
PubMed Abstract available

WU H, Xu X, Zheng A, Wang W, et al
TIPE1 Inhibits Hepatic Steatosis, Inflammation, and Fibrosis by Suppressing Polyubiquitination of ASK1.
Hepatology. 2021 Mar 13. doi: 10.1002/hep.31801.
PubMed Abstract available

BALDASSARRE M, Naldi M, Zaccherini G, Bartoletti M, et al
Determination of effective albumin in patients with decompensated cirrhosis: clinical and prognostic implications.
Hepatology. 2021 Mar 12. doi: 10.1002/hep.31798.
PubMed Abstract available

PONZIANI FR, Gasbarrini A, Pompili M
Letter to the Editor. Restructuring the Gut Microbiota of Cirrhotic Patients after HCV Eradication: a Matter of Time?
Hepatology. 2021 Mar 5. doi: 10.1002/hep.31784.
PubMed Abstract available

ZHOU Y, Chen Y, Zhang X, Xu Q, et al
Brg1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
Hepatology. 2021 Mar 2. doi: 10.1002/hep.31780.
PubMed Abstract available

February 2021

NEWBERRY EP, Hall Z, Xie Y, Molitor EA, et al
Liver specific deletion of mouse Tm6sf2 promotes steatosis, fibrosis and hepatocellular cancer.
Hepatology. 2021 Feb 27. doi: 10.1002/hep.31771.
PubMed Abstract available

JOHN BV, Aitcheson G, Schwartz KB, Shabbir Khakoo N, et al
Male Gender is Associated with Higher Rates of Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis.
Hepatology. 2021 Feb 26. doi: 10.1002/hep.31776.
PubMed Abstract available

HUANG DQ, Yeo YH, Nguyen MH
Letter to the Editor: HCC surveillance in cirrhosis patients: Is the real-world situation even worse than reported?
Hepatology. 2021 Feb 22. doi: 10.1002/hep.31760.
PubMed Abstract available

RICH NE, Parikh ND, Singal AG
HCC Surveillance in Cirrhosis Patients: Room for Improvement.
Hepatology. 2021 Feb 22. doi: 10.1002/hep.31762.
PubMed Abstract available

LAN T, Yu Y, Zhang J, Li H, et al
Cordycepin Ameliorates Nonalcoholic Steatohepatitis via Activation of AMP-Activated Protein Kinase Signaling Pathway.
Hepatology. 2021 Feb 12. doi: 10.1002/hep.31749.
PubMed Abstract available

DAT NQ, Thuy LTT, Hieu VN, Hai H, et al
6His-tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.
Hepatology. 2021 Feb 11. doi: 10.1002/hep.31752.
PubMed Abstract available

PARK H, Jiang X, Song HJ, Lo Re V 3rd, et al
The Impact of Direct-acting Antiviral Therapy on End Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders.
Hepatology. 2021 Feb 5. doi: 10.1002/hep.31732.
PubMed Abstract available

SANSOE G, Aragno M, Wong F
Covid-19 and liver cirrhosis: focus on the non-classical renin-angiotensin system and implications for therapy.
Hepatology. 2021 Feb 1. doi: 10.1002/hep.31728.
PubMed Abstract available

PIROLA CJ, Sookoian S
NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions.
Hepatology. 2021;73:479-482.
PubMed

January 2021

ITOH A, Adams D, Huang W, Wu Y, et al
Enoxacin upregulates microRNA biogenesis and downregulates cytotoxic CD8 T cell function in autoimmune cholangitis.
Hepatology. 2021 Jan 19. doi: 10.1002/hep.31724.
PubMed Abstract available

CARACENI P, Vargas V, Sola E, Alessandria C, et al
The use of Rifaximin in Patients with Cirrhosis.
Hepatology. 2021 Jan 9. doi: 10.1002/hep.31708.
PubMed Abstract available

WELLHONER F, Doscher N, Woelfl F, Vital M, et al
Eradication of chronic HCV infection: improvement of dysbiosis only in patients without liver cirrhosis.
Hepatology. 2021 Jan 7. doi: 10.1002/hep.31700.
PubMed Abstract available

NORTHUP PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, et al
Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.
Hepatology. 2021;73:366-413.
PubMed

December 2020

ELKRIEF L, Lazareth M, Chevret S, Paradis V, et al
Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension.
Hepatology. 2020 Dec 21. doi: 10.1002/hep.31688.
PubMed Abstract available

KEISHAM A, Taneja S, Roy A, Singh V, et al
ABIDE in NAFLD: A potential game changer in a select cohort of cirrhosis.
Hepatology. 2020 Dec 4. doi: 10.1002/hep.31667.
PubMed Abstract available

ANAND A, Pathak P, Shalimar
Letter to the editor: ABIDE model for predicting decompensation in non-alcoholic fatty liver disease-related cirrhosis.
Hepatology. 2020 Dec 3. doi: 10.1002/hep.31668.
PubMed Abstract available

SELCK TJ, Bok J, Amintavakoli R
Letter to the Editor: Do Weather and Sunlight Really Affect Alcohol Consumption?
Hepatology. 2020;72:2239.
PubMed

VENTURA-COTS M, Abraldes JG, Bataller R
Reply.
Hepatology. 2020;72:2239-2240.
PubMed

November 2020

SIMON TG, Chan AT, Huttenhower C
Microbiome Biomarkers: One Step Closer in NAFLD-Cirrhosis.
Hepatology. 2020 Nov 29. doi: 10.1002/hep.31660.
PubMed Abstract available

HERNANDEZ-MEZA G, von Felden J, Gonzalez-Kozlova EE, Garcia-Lezana T, et al
DNA methylation profiling of human hepatocarcinogenesis.
Hepatology. 2020 Nov 25. doi: 10.1002/hep.31659.
PubMed Abstract available

SIMONETTO DA, Shah VH, Kamath PS
Surgery in patients with cirrhosis: as much an art as science.
Hepatology. 2020 Nov 21. doi: 10.1002/hep.31643.
PubMed Abstract available

IOANNOU GN, Liang PS, Locke E, Green P, et al
Cirrhosis and SARS-CoV-2 infection in US Veterans: risk of infection, hospitalization, ventilation and mortality.
Hepatology. 2020 Nov 21. doi: 10.1002/hep.31649.
PubMed Abstract available

SETIAWAN VW, Rosen HR
Stratification of residual risk of hepatocellular carcinoma following HCV clearance with DAA in patients with advanced fibrosis and cirrhosis.
Hepatology. 2020 Nov 18. doi: 10.1002/hep.31639.
PubMed Abstract available

KOKUDO T
Evaluating Liver Function in Patients With Cirrhosis.
Hepatology. 2020 Nov 13. doi: 10.1002/hep.31626.
PubMed Abstract available

LOOMBA R, Noureddin M, Kowdley KV, Kohli A, et al
Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH.
Hepatology. 2020 Nov 10. doi: 10.1002/hep.31622.
PubMed Abstract available

GAO J, Wei B, Liu M, Hirsova P, et al
Endothelial p300 promotes portal hypertension and hepatic fibrosis through CCL2-mediated angiocrine signaling.
Hepatology. 2020 Nov 7. doi: 10.1002/hep.31617.
PubMed Abstract available

SMETS L, Verbeek J, Korf H, van der Merwe S, et al
Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate.
Hepatology. 2020 Nov 3. doi: 10.1002/hep.31613.
PubMed Abstract available

BANINI BA, P Kumar D, Cazanave S, Seneshaw M, et al
Identification of a metabolic, transcriptomic and molecular signature of PNPLA3-mediated acceleration of steatohepatitis.
Hepatology. 2020 Nov 1. doi: 10.1002/hep.31609.
PubMed Abstract available

October 2020

LONG MT, Zhang X, Xu H, Liu CT, et al
Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: The Framingham Heart Study.
Hepatology. 2020 Oct 30. doi: 10.1002/hep.31608.
PubMed Abstract available

BROWN SA, Izzy M, Watt KD
Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underutilized Potential.
Hepatology. 2020 Oct 12. doi: 10.1002/hep.31595.
PubMed Abstract available

ALONSO S, Manzano ML, Gea F, Gutierrez ML, et al
A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV-advanced fibrosis.
Hepatology. 2020 Oct 6. doi: 10.1002/hep.31588.
PubMed Abstract available

LA MURA V, Villanueva C, Abraldes JG, Bosch J, et al
Reply.
Hepatology. 2020;72:1494-1495.
PubMed

KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
Hepatology. 2020;72:1310-1326.
PubMed Abstract available

September 2020

CALZADILLA-BERTOT L, Vilar-Gomez E, Wong VW, Romero-Gomez M, et al
ABIDE: an accurate predictive model of liver decompensation in patients with non-alcoholic fatty liver-related cirrhosis.
Hepatology. 2020 Sep 25. doi: 10.1002/hep.31576.
PubMed Abstract available

LOK AS, Perrillo R, Lalama CM, Fried MW, et al
medLow Incidence of Adverse Outcomes in Adults with Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy.
Hepatology. 2020 Sep 16. doi: 10.1002/hep.31554.
PubMed Abstract available

MARTIN N, Ziegler DV, Parent R, Bernard D, et al
Hepatic Stellate Cell Senescence in Liver Tumorigenesis.
Hepatology. 2020 Sep 15. doi: 10.1002/hep.31556.
PubMed Abstract available

LAPOINTE-SHAW L, Chung H, Holder L, Kwong JC, et al
Diagnosis of Chronic Hepatitis B Peri-Complication: Risk factors and Trends over Time.
Hepatology. 2020 Sep 15. doi: 10.1002/hep.31557.
PubMed Abstract available

CHEN L, Zhou T, White T, O'Brien A, et al
The apelin-apelin receptor axis triggers cholangiocyte proliferation and liver fibrosis during mouse models of cholestasis.
Hepatology. 2020 Sep 7. doi: 10.1002/hep.31545.
PubMed Abstract available

KUMAR M
Reply.
Hepatology. 2020;72:1160.
PubMed

August 2020

LEUNG KK, James PD, Jaberi A, Hirschfield GM, et al
Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding.
Hepatology. 2020 Aug 11. doi: 10.1002/hep.31519.
PubMed Abstract available

KULKARNI AV, Sharma M, Kumar P, Gupta R, et al
Midodrine for Hepatic Hydrothorax.
Hepatology. 2020 Aug 8. doi: 10.1002/hep.31513.
PubMed Abstract available

GINDIN Y, Chung C, Jiang Z, Zhou JZ, et al
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Novel Drivers of Disease Progression in Primary Sclerosing Cholangitis.
Hepatology. 2020 Aug 3. doi: 10.1002/hep.31488.
PubMed Abstract available

WEN Y, Ju C
MER Proto-Oncogene Tyrosine Kinase: A Novel Potential Target to Treat Nonalcoholic Steatohepatitis Fibrosis.
Hepatology. 2020;72:772-774.
PubMed

July 2020

SCHULTHEISS C, Simnica D, Willscher E, Oberle A, et al
Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis.
Hepatology. 2020 Jul 21. doi: 10.1002/hep.31473.
PubMed Abstract available

JIANG L, Lang S, Duan Y, Zhang X, et al
Intestinal virome in patients with alcoholic hepatitis.
Hepatology. 2020 Jul 12. doi: 10.1002/hep.31459.
PubMed Abstract available

THAN NN, Cataluna JG, Majumdar A
Acute confusion post liver transplantation: HE or not HE, that is the question.
Hepatology. 2020 Jul 6. doi: 10.1002/hep.31452.
PubMed Abstract available

SU T, Iwakiri Y
Endothelial Leukocyte Cell-Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin-Like and Epidermal Growth Factor-Like Domains 1 Signaling in Liver Fibrosis.
Hepatology. 2020;72:347-349.
PubMed

YANG JD, Mara KC, Gores GJ, Roberts LR, et al
Reply.
Hepatology. 2020;72:364-365.
PubMed

YANG JD, Mara KC, Gores GJ, Roberts LR, et al
REPLY.
Hepatology. 2020;72:362-363.
PubMed

LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
Hepatology. 2020;72:359-360.
PubMed

June 2020

BANINI BA, Alwatari Y, Stovall M, Ogden N, et al
Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence-Based Review and Guidance.
Hepatology. 2020 Jun 25. doi: 10.1002/hep.31434.
PubMed Abstract available

CHASCSA DM, Ferre EMN, Hadjiyannis Y, Alao H, et al
APECED-Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data from a Large Predominantly American Cohort.
Hepatology. 2020 Jun 17. doi: 10.1002/hep.31421.
PubMed Abstract available

ZHANG J, Li Y, Liu Q, Huang Y, et al
Sirt6 alleviated liver fibrosis by deacetylating conserved lysine 54 on Smad2 in hepatic stellate cells.
Hepatology. 2020 Jun 14. doi: 10.1002/hep.31418.
PubMed Abstract available

KARDASHIAN A, Ge J, McCulloch CE, Kappus MR, et al
Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates.
Hepatology. 2020 Jun 3. doi: 10.1002/hep.31406.
PubMed Abstract available

LUCEY MR, Singal AK
Integrated Treatment of Alcohol Use Disorder in Patients With Alcohol-Associated Liver Disease: An Evolving Story.
Hepatology. 2020;71:1891-1893.
PubMed

May 2020

IZZY M, VanWagner LB, Lin G, Altieri M, et al
Reply.
Hepatology. 2020;71:1884-1885.
PubMed

April 2020

MELE D, Oliviero B, Mantovani S, Ludovisi S, et al
Adaptive Natural Killer Cell Functional Recovery in Hepatitis C Virus Cured Patients.
Hepatology. 2020 Apr 13. doi: 10.1002/hep.31273.
PubMed Abstract available

DAVE S, Park S, Murad MH, Barnard A, et al
Comparative Effectiveness of Entecavir vs Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: a Systematic Review and Meta-analysis.
Hepatology. 2020 Apr 10. doi: 10.1002/hep.31267.
PubMed Abstract available

SEHRAWAT TS, Arab JP, Liu M, Amrollahi P, et al
Circulating extracellular vesicles carrying sphingolipid cargo for the diagnosis and dynamic risk profiling of alcoholic hepatitis.
Hepatology. 2020 Apr 4. doi: 10.1002/hep.31256.
PubMed Abstract available

RATZIU V
Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed.
Hepatology. 2020;71:1146-1149.
PubMed

WANG S, Friedman SL
Taming the Savage Breast From Within: Transcription Factor 21, a Regulator of Stellate Cell Deactivation.
Hepatology. 2020;71:1150-1153.
PubMed

March 2020

KAMAL H, Westman G, Falconer K, Duberg AS, et al
Long-term study of hepatitis D infection at secondary care centers: the impact of viremia on liver-related outcomes.
Hepatology. 2020 Mar 7. doi: 10.1002/hep.31214.
PubMed Abstract available

TERKELSEN MK, Bendixen SM, Hansen D, Scott EAH, et al
Transcriptional dynamics of hepatic sinusoid-associated cells after liver injury.
Hepatology. 2020 Mar 7. doi: 10.1002/hep.31215.
PubMed Abstract available

AZAD AI, Krishnan A, Troop L, Li Y, et al
Targeted Apoptosis Of Ductular Reactive Cells Reduces Hepatic Fibrosis In A Mouse Model of Cholestasis.
Hepatology. 2020 Mar 3. doi: 10.1002/hep.31211.
PubMed Abstract available

WONG GL, Wong VW
Reply.
Hepatology. 2020;71:1134.
PubMed

LO GH
Letter to the Editor: Could Variceal Screening Stratified by Liver/Spleen Stiffness Replace the Role of Endoscopy?
Hepatology. 2020;71:1133.
PubMed

UNALP-ARIDA A, Ruhl CE
Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
Hepatology. 2020;71:820-834.
PubMed Abstract available

AJMERA VH, Liu A, Singh S, Yachoa G, et al
Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
Hepatology. 2020;71:849-860.
PubMed Abstract available

DE CHIARA F, Thomsen KL, Habtesion A, Jones H, et al
Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease.
Hepatology. 2020;71:874-892.
PubMed Abstract available

CHANG Y, Ryu S, Kim Y, Cho YK, et al
Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis.
Hepatology. 2020;71:861-873.
PubMed Abstract available

February 2020

SHARMA A, Verma AK, Kofron M, Kudira R, et al
Lipopolysaccharide Reverses Hepatic Stellate Cell Activation via Modulation of cMyb, SMADs and C/EBP Transcription Factors.
Hepatology. 2020 Feb 16. doi: 10.1002/hep.31188.
PubMed Abstract available

DEBES JD, Boonstra A, de Knegt RJ
NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse.
Hepatology. 2020 Feb 10. doi: 10.1002/hep.31170.
PubMed Abstract available

KUMAR S, Verma AK, Rani R, Sharma A, et al
Hepatic deficiency of augmenter of liver regeneration predisposes to nonalcoholic steatohepatitis and fibrosis.
Hepatology. 2020 Feb 7. doi: 10.1002/hep.31167.
PubMed Abstract available

JOPHLIN LL, Cao S, Shah VH
The transcriptome of hepatic fibrosis revealed by single cell RNA sequencing.
Hepatology. 2020 Feb 3. doi: 10.1002/hep.31155.
PubMed Abstract available

STERLING RK, King WC, Wahed AS, Kleiner DE, et al
Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults.
Hepatology. 2020;71:411-421.
PubMed Abstract available

SCHUMACHER JD, Kong B, Wu J, Rizzolo D, et al
Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development.
Hepatology. 2020;71:670-685.
PubMed Abstract available

January 2020

DOS SANTOS MARCON P, de Mattos AZ, Alves de Mattos A
Letter to the editor: Co-infection of human immunodeficiency virus with hepatitis C virus: a change of paradigm.
Hepatology. 2020 Jan 21. doi: 10.1002/hep.31123.
PubMed Abstract available

JIANG JX, Fish SR, Tomilov A, Li Y, et al
Non-phagocytic Activation of NOX2 is Implicated in Progressive Non-alcoholic Steatohepatitis During Aging.
Hepatology. 2020 Jan 17. doi: 10.1002/hep.31118.
PubMed Abstract available

RATZIU V, Sanyal A, Harrison SA, Wong VW, et al
Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108.
PubMed Abstract available

December 2019

GAO E, Cheema H, Waheed N, Mushtaq I, et al
OSTalpha deficiency: A disorder with cholestasis, liver fibrosis and congenital diarrhea.
Hepatology. 2019 Dec 21. doi: 10.1002/hep.31087.
PubMed Abstract available

KARVAR S, Ansa-Addo EA, Suda J, Singh S, et al
Moesin, an ERM family member, regulates hepatic fibrosis.
Hepatology. 2019 Dec 20. doi: 10.1002/hep.31078.
PubMed Abstract available

PROESCHOLD-BELL RJ, Evon DM, Yao J, Niedzwiecki D, et al
A randomized controlled trial of an integrated alcohol reduction intervention in patients with hepatitis C infection.
Hepatology. 2019 Dec 5. doi: 10.1002/hep.31058.
PubMed Abstract available

November 2019

EATON JE, Vuppalanchi R, Reddy R, Sathapathy S, et al
Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid.
Hepatology. 2019 Nov 4. doi: 10.1002/hep.31017.
PubMed Abstract available

October 2019

LIU F, Goh GB, Tiniakos D, Wee A, et al
qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
Hepatology. 2019 Oct 10. doi: 10.1002/hep.30986.
PubMed Abstract available

POLI E, Kounis I, Guettier C, Verstuyft C, et al
Post-Liver Transplantation Sinusoidal Obstruction Syndrome With Refractory Ascites Induced by Mycophenolate Mofetil.
Hepatology. 2019 Oct 9. doi: 10.1002/hep.30984.
PubMed Abstract available

September 2019

LIU Y, Chen K, Li F, Gu Z, et al
Probiotic LGG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice.
Hepatology. 2019 Sep 30. doi: 10.1002/hep.30975.
PubMed Abstract available

NAKANO Y, Kamiya A, Sumiyoshi H, Tsuruya K, et al
A novel deactivation factor of fibrogenic hepatic stellate cells induces regression of liver fibrosis in mice.
Hepatology. 2019 Sep 24. doi: 10.1002/hep.30965.
PubMed Abstract available

KIM YC, Jung H, Seok S, Zhang Y, et al
MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice.
Hepatology. 2019 Sep 24. doi: 10.1002/hep.30966.
PubMed Abstract available

DUSZYNSKI CC, Avati V, Lapointe AP, Scholkmann F, et al
Near infrared spectroscopy reveals brain hypoxia and cerebrovascular dysregulation in primary biliary cholangitis.
Hepatology. 2019 Sep 19. doi: 10.1002/hep.30920.
PubMed Abstract available

ASRANI SK, Jennings LW, Kim WR, Kamath P, et al
MELD-GRAIL-Na: Glomerular filtration rate and mortality on Liver-Transplant Waiting List.
Hepatology. 2019 Sep 16. doi: 10.1002/hep.30932.
PubMed Abstract available

MOORING M, Fowl BH, Lum SZC, Liu Y, et al
Hepatocyte Stress Increases Expression of YAP and TAZ in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis.
Hepatology. 2019 Sep 10. doi: 10.1002/hep.30928.
PubMed Abstract available

TARDELLI M, Bruschi FV, Fuchs CD, Claudel T, et al
Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis.
Hepatology. 2019 Sep 10. doi: 10.1002/hep.30929.
PubMed Abstract available

August 2019

MATYAS C, Erdelyi K, Trojnar E, Zhao S, et al
Interplay of liver-heart inflammatory axis and cannabinoid 2 receptor signalling in an experimental model of hepatic cardiomyopathy.
Hepatology. 2019 Aug 30. doi: 10.1002/hep.30916.
PubMed Abstract available

MOHANTY SK, Lobeck I, Donnelly B, Dupree P, et al
Rotavirus reassortant induced murine model of liver fibrosis parallels human biliary atresia.
Hepatology. 2019 Aug 23. doi: 10.1002/hep.30907.
PubMed Abstract available

MCCULLOCH K, Romero N, MacLachlan J, Allard N, et al
Modelling progress towards elimination of hepatitis B in Australia.
Hepatology. 2019 Aug 16. doi: 10.1002/hep.30899.
PubMed Abstract available

July 2019

KYRITSI K, Chen L, O'Brien A, Francis H, et al
Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.
Hepatology. 2019 Jul 25. doi: 10.1002/hep.30880.
PubMed Abstract available

February 2019

HARRISON SA, Rossi SJ, Paredes AH, Trotter JF, et al
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis.
Hepatology. 2019 Feb 25. doi: 10.1002/hep.30590.
PubMed Abstract available

December 2018

VILAR-GOMEZ E, Vuppalanchi R, Gawrieh S, Ghabril M, et al
Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis.
Hepatology. 2018 Dec 1. doi: 10.1002/hep.30368.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.